US begins human trial of coronavirus vaccine

US begins human trial of coronavirus vaccine

Tuesday, March 17, 2020

Print this page Email A Friend!


WASHINGTON, DC, United States (AFP) — The first human trial to evaluate a candidate vaccine against the new coronavirus has begun in Seattle, US health officials said yesterday, raising hopes in the global fight against the disease.

But it may be another year to 18 months before it becomes available, once it has passed more trial phases to prove it works and is safe.

The vaccine is called mRNA-1273 and was developed by US National Institutes of Health (NIH) scientists and collaborators at biotechnology company Moderna, which is based in Cambridge, Massachusetts.

“The open-label trial will enrol 45 healthy adult volunteers ages 18 to 55 years over approximately six weeks,” the NIH said. “The first participant received the investigational vaccine today.”

Funding was also provided by the Oslo-based Coalition for Epidemic Preparedness Innovations.

There are currently no approved vaccines or treatments against the coronavirus disease, known as COVID-19, which has infected more than 175,000 people across the world since it was first identified in central China in late December.

It has claimed 7,000 deaths, according to an AFP tally, most of them in China, followed by Italy.

“Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority,” said Anthony Fauci, head of infectious diseases at the NIH, using the technical name for the virus that is believed to have originated in bats.

“This Phase 1 study, launched in record speed, is an important first step toward achieving that goal.”

The Seattle trial will study the impact of different doses delivered by intramuscular injection in the upper arm, with participants monitored for side effects like soreness or fever.

Coronaviruses are spherical and have spikes protruding from their surface, giving them a crown-like appearance. The spike binds to human cells, allowing the virus to gain entry.

The Moderna candidate vaccine carries the genetic information of this spike in a substance called “messenger RNA”.

Injecting human tissue with the spike's messenger RNA makes it grow inside the body, thereby eliciting an immune response without having actually infected a person with the full-blown virus.

Pharmaceuticals and research labs around the world are racing to develop both treatments and vaccines for the new coronavirus.

An antiviral treatment called Remdesivir, made by US-based Gilead Sciences, is already in the final stages of clinical trials in Asia, and doctors in China have reported it has proven effective in fighting the disease.

But only randomised trials allow scientists to know for sure whether it really helps or whether patients would have recovered without it.

Another US pharma called Inovio, which is creating a DNA-based vaccine, has said it will enter clinical trials next month.

Regeneron is trying to isolate coronavirus-fighting antibodies that can be administered intravenously to confer temporary immunity, and hopes to start human trials by summer.

According to the World Health Organization, 80 per cent of COVID-19 cases are mild, 14 per cent are severe, and about five per cent are critical — resulting in severe respiratory illness that causes the lungs to fill with fluid which in turn prevents oxygen from reaching organs.

Patients with mild cases recover in a week or two, while severe cases can take six or more weeks.

Recent estimates suggest about one per cent of all infected people die.


Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at http://bit.ly/epaper-login


ADVERTISEMENT




POST A COMMENT

HOUSE RULES

1. We welcome reader comments on the top stories of the day. Some comments may be republished on the website or in the newspaper � email addresses will not be published.

2. Please understand that comments are moderated and it is not always possible to publish all that have been submitted. We will, however, try to publish comments that are representative of all received.

3. We ask that comments are civil and free of libellous or hateful material. Also please stick to the topic under discussion.

4. Please do not write in block capitals since this makes your comment hard to read.

5. Please don't use the comments to advertise. However, our advertising department can be more than accommodating if emailed: advertising@jamaicaobserver.com.

6. If readers wish to report offensive comments, suggest a correction or share a story then please email: community@jamaicaobserver.com.

7. Lastly, read our Terms and Conditions and Privacy Policy



comments powered by Disqus
ADVERTISEMENT

Poll

ADVERTISEMENT
ADVERTISEMENT

Today's Cartoon

Click image to view full size editorial cartoon
ADVERTISEMENT